Company Filing History:
Years Active: 2011-2012
Title: David Joseph Garmene: Innovator in Melanin Concentrating Hormone Antagonists
Introduction
David Joseph Garmene is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target melanin concentrating hormone receptors. With a total of three patents to his name, Garmene's work is paving the way for advancements in obesity treatment and related diseases.
Latest Patents
Garmene's latest patents focus on MCH receptor antagonists. The first patent describes a melanin concentrating hormone antagonist compound of a specific formula, which includes various defined components. This compound is recognized for its potential utility in treating obesity and related diseases. The second patent reiterates similar findings, emphasizing the importance of these compounds in the pharmaceutical landscape.
Career Highlights
David Joseph Garmene is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has allowed him to contribute to innovative research and development in the field of obesity treatment. Garmene's expertise and dedication to his work have positioned him as a valuable asset in the industry.
Collaborations
Throughout his career, Garmene has collaborated with notable colleagues, including Kevin Matthew Gardinier and Erik James Hembre, II. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their shared field of research.
Conclusion
David Joseph Garmene's contributions to the development of melanin concentrating hormone antagonists highlight his role as an influential inventor in the pharmaceutical industry. His work continues to inspire advancements in the treatment of obesity and related diseases.